Hepatitis C Research

Page Three

   

2002 HCV Related Plenary Highlights from DDW

(back to :2001 Highlights from DDW)

BACK TO: Reports from Digestive Disease Week 2003:

Orlando Fla, May 17-22

  Prevention of Spread of HCV
  Sexual Activity as a Risk Factor for Hepatitis C Infection
  Maternal-Infant Transmission
  Introduction to Therapy of Hepatitis C
  Optimal Therapy of Hepatitis C
  Retreatment of Patients With Chronic Hepatitis C
  Treatment for Hepatitis C: A Systematic Review
  Utilization of Virologic Testing in the Treatment of Chronic Hepatitis C
  The Role of Liver Biopsy in Therapy of Chronic Hepatitis C
  Children with Hepatitis C
  Patients with Normal ALT Levels
  Patients with Advanced Disease
  Therapy of Acute Hepatitis C
  Hepatitis C and HIV
  Injection Drug Use and Hepatitis C
  Alcohol and Hepatitis C
  Special Populations
  Side Effects of Therapy and Management
  Future Therapy of Hepatitis C
  Pegylated Interferon Alfa-2b plus Ribavirin in Patients with Chronic Hepatitis C: A Trial in Prior Nonresponders to Interferon Monotherapy or Combination Therapy and in Combination Therapy Relapsers
  Pegylated Interferon Alfa 2b (PEG-IFN) and Ribavirin for Hepatitis C Patients who Were Nonresponders to Previous Therapy
  Prediction of Early Virologic Response to Treatment with 40KD Pegylated (PEG)-Interferon (IFN) Alfa2a/Ribavirin in Patients with Chronic Hepatitis C (Genotype 1)
  Interferon Alfa-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT: Final Results
  Amantadine Therapy for Chronic Hepatitis C: A Randomized Double-Blind Placebo Controlled Trial
  Pegylated (40 kDa, Branched) Interferon Alfa-2a (PEG-IFN) and Ribavirin (RIBA) in IFN-naive Patients with Hepatitis C and Advanced Fibrosis/Cirrhosis: Interim Results of a Randomized, Controlled Trial
  Pegylated Interferon Alfa-2b (PEG-IFN) Plus Ribavirin Versus PEG-IFN for Treatment of HIV/HCV Co-infected Patients (pts): An Open, Multicenter, Randomized Trial
  Pegylated Interferon alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C Infection in African Americans and Non-Hispanic Whites. A Preliminary Report.
  Sampling Variability on Percutaneous Liver Biopsy in Patients with Chronic Hepatitis C Virus Infection.
  The Impact of Intervening Substance Abuse on Hepatitis C Treatment Outcomes in Recovering Injection Drug Users: An Interim Analysis
  Alpha Feto-Protein Levels in Hepatitis C Subjects Treated with Combination Therapy: Abnormal Levels Decline with Therapy
  Does Normal ALT Exclude Severe Hepatic Fibrosis in Patients with Chronic Hepatitis C?
  Hepatitis C Treatments in Current Clinical Development
Reviewed Feb 2004
HOME Liver Cancer
FAQ Great Place To Start Autoimmune Hepatitis
Have You Just Been Diagnosed ? Other Medical Conditions & HCV
Glossary HCV Worldwide News & Research
History Of HCV HCV News Archives 2001-2002
Your Liver Functions Internet Conference Reports on All New and Current HCV Therapies
Symptoms Of HCV Nutrition & HCV
Transmission Of HCV Interviews: Members & Professionals
Sex And HCV HCV Support Groups Listed By State
Understanding Your Blood Tests  Labs Transplant Support Groups Listed By State
Monitoring Blood Work On Treatment Insurance, Financial Aid & Free Meds
Liver Biopsy Understanding Your Results How to Find a Doctor & What to Ask
Viral Loads Members Share Their First Shot Experience
Genotypes Shared Stories From Our  Members
Infergen Your Questions & HCV
 Inhibitors &  New Therapies Chat Room & Message Boards
Peg Intron & Pegasys Books On HCV
Help With Side Effects During Treatment Food For The Soul Inspirational Stories
Drug Interactions & Treatment Informative Links
Latest HCV Trials Pictures Of Our Members
Liver Fibrosis What's New at Janis and Friends
Cirrhosis Sign Our Guestbook
Transplants Contact Us mailto:JansDream@angelhaven.com
Current Transplant Research In Memory Of Janis